New Drugs From Biogen, Octapharma, Alcon Passed By Europe’s CHMP
This article was originally published in The Pink Sheet Daily
Executive Summary
Europe’s top scientific advisory panel, the Committee for Medicinal Products for Human Use, recommended a new long-acting beta-interferon in MS, a highly pure recombinant Factor VIII, and a new combination eye-drop for glaucoma, but confirmed its previous rejections of Novartis’s heart failure therapy, Teva’s oral MS medicine and AB Science’s pancreatic cancer product.